An algorithm based on near-infrared spectroscopy (NIRS) is able to correctly identify more than 85% of men classified as obstructed using catheter urodynamics, according to study findings published in the Canadian Journal of Urology (2008; 1515:4241-8).
An algorithm based on near-infrared spectroscopy (NIRS) is able to correctly identify more than 85% of men classified as obstructed using catheter urodynamics, according to study findings published in the Canadian Journal of Urology (2008; 1515:4241-8).
In the study, 70 male patients with lower urinary tract symptoms underwent uroflow and urodynamic pressure flow studies with simultaneous transcutaneous monitoring with NIRS (Urodynamix Technologies Ltd., Vancouver, BC) and measurement of post-void residual volume via ultrasound. The NIRS algorithm correctly identified those diagnosed as obstructed by conventional urodynamic classification in 24 of 28 subjects (sensitivity, 85.71%) and those diagnosed as unobstructed in 24 of 27 subjects (specificity, 88.89%), reported co-authors Andrew J. Macnab, MD, and Lynn Stothers, MD, of The University of British Columbia.
In a related article in the same issue of the journal, Drs. Macnab and Stothers reported on the feasibility of urologic monitoring with NIRS instrumentation and the potential diagnostic value of the technology (Can J Urol 2008; 15:4233-40).
In an accompanying editorial, Canadian Journal of Urology Editor-in-Chief Gabriel P. Haas, MD, called NIRS “a new modality waiting for widespread utilization.”
Drs. Macnab and Stothers are on the medical advisory board of Urodynamix Technologies.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.